MAY 8 2026
Genentech — Ocrevus (ocrelizumab) $RHHBY
for relapsing-remitting multiple sclerosis
FDA approved Ocrevus (ocrelizumab) IV infusion for relapsing-remitting multiple sclerosis in pediatric patients aged 10 and older.
About
Multiple sclerosis is an autoimmune disease where the immune system mistakenly attacks the protective myelin coating around nerve fibers, disrupting communication between the brain and body. Ocrevus is an antibody drug that targets and depletes specific immune cells (B cells) thought to drive this harmful attack on the nervous system. By reducing these overactive immune cells, Ocrevus may help slow the progression of MS and preserve patients' physical and cognitive function.
Pivotal trial
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Ocrevus
- OCREVUS sales grow 9% in 2025, driven by broad MS treatment and new subcutaneous form - Pluang
- Ocrevus: FDA Approves Intravenous Targeted Therapy for Children Aged 10 Years or Older With Relapsing-Remitting Multiple Sclerosis - WebMD
- In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS - Multiple Sclerosis News Today
- FDA Approves Ocrelizumab (Ocrevus) for Relapsing-Remitting Multiple Sclerosis In Patients Over 10 Years Old - Patient Care Online
- FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis - Neurology Live